Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GH Research PLC filings document foreign private issuer current reports for a clinical-stage biopharmaceutical company developing mebufotenin product candidates for depression. The company’s Form 6-K reports furnish press releases, corporate presentations, manuscripts, and conference materials related to GH001 in treatment-resistant depression, including Phase 2b results, open-label extension data, and FDA/IND regulatory updates.
The filing record also covers operating and financial results, material-event disclosures, shareholder voting matters, capital-structure information, material agreements, and clinical or regulatory disclosures. These documents describe the company’s research and development focus, product-candidate pipeline, governance reporting, and formal exhibits used to communicate trial publications and business updates.
GH Research PLC (NASDAQ: GHRS) filed a Form 6-K reporting that it has submitted a complete response to the U.S. FDA concerning the clinical hold on its Investigational New Drug (IND) application for GH001. The submission was made in June 2025 and disclosed to investors via a press release dated 20 June 2025 (attached as Exhibit 99.1).
The filing does not disclose FDA feedback, timelines, or whether the hold will be lifted. Management expressly states it will not update the press release or forward-looking statements, underscoring regulatory uncertainty. No financial statements, earnings metrics, or other operational updates accompany the filing.
Investor takeaway: The response filing is an incremental regulatory step that could enable clinical trials of GH001 to resume if the FDA is satisfied. However, material impact remains contingent on the FDA’s decision; therefore, the risk profile for GHRS is largely unchanged until further notice.